We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.
Cayman Galectin 9 Short Variant (human, recombinant)
Product Description
Galectin 9 is a β-galactoside-binding protein encoded by the LGALS9 gene and a member of the galectin family. It contains two non-identical carbohydrate recognition domains (CRDs) joined by a peptide linker, the length of which depends on alternative splicing of the LGALS9 gene, which produces a short, medium, or long variant of the protein., The non-identical CRDs are responsible for binding to different types of saccharide ligands with the N-terminal CRD (NCRD) preferring more complex glycoconjugates. Galectin 9 is localized to the cytosol, nucleus, and extracellular matrix and is expressed primarily in immune-related tissues and cells. When expressed on immune or tumor cells, galectin 9 binds to glycosylated sites on the immunoregulatory protein TIM-3 and activates signaling that impairs immune synapse formation leading to T cell anergy or apoptosis. It also binds to the transmembrane glycoprotein CD44 on osteoblasts, leading to their proliferation, and it has a role in cell adhesion by preventing hyaluronic acid from binding to CD44. The short variant of galectin 9 acts as an eosinophil chemoattractant. It also activates CD4+ T cell populations and induces naïve T cells to acquire a central memory T cell (Tcm) phenotype. Galectin 9 was originally identified as a tumor antigen in patients with Hodgkin’s disease. It is expressed to a lower extent in tumor cells compared with non-tumor cells but is increased in leukemia and colon cancer cell lines. Increased expression of the short variant of galectin 9 inhibits or enhances adhesion in breast or colon cancer cell lines, respectively. The expression of the short variant of galectin 9 is increased by interferon γ (IFN-γ) in synovial fibroblasts isolated from patients with rheumatoid arthritis. Caymans Galectin 9 Short Variant (human, recombinant) protein is a disulfide-linked homodimer. The reduced monomer, comprised of galectin 9 (amino acids 2-323) fused to human IgG1 Fc at its N-terminus, consists of 554 amino acids and has a calculated molecular weight of 61.8 kDa.
WARNING This product is not for human or veterinary use.
Technical Information
- Gal-9S
- HUAT
- Human Urate Transporter
- Lectin Galactoside-binding Soluble 9
- LGALS9A
Shipping & Storage Information
| SKU | CAYM-32012-50 |
|---|---|
| Supplier Part Number | 32012-50 |
| UM | EA |
| UNSPSC | 12352200 |
| Manufacturer | Cayman |
| MSDS URL | Click here |
| Temperature | -80 |
| Refrigerated-Frozen | Y |
| CountryOfOrigin | United States |
| ProductLine | CAYM |
| Qty | 1 |
| MinOrderQty | 1 |
| Weight | 7.000000 |
| Lead Time | 5 |
| Hazardous | N |
| Energy Star | No |
| Green | No |
| Controlled | N |